... 4.4 (0 to without appropriate 18.3) washout Placebo: 7.3 (5.2 to 8.2) Difference ... between) 98.5 (6.4) difference (p-value) washout for 4 −2.22 (p=0.0097) weeks, and 150mg placebo every 12 hours for 4 weeks OR (2) ...

... of 95 to 109 mm Hg, after a placebo washout period, to receive placebo or one of six ... maintenance phase, each patient entered a four-week placebo washout phase. Patients who had been randomly assigned to ...

... four- weeks, and 150mg Mean, percentage value) week washout placebo every 12 hours points (SD) −2.22 (p= ... 4) for 4 weeks OR (2) 150mg of placebo every 12 hours for 4 weeks, washout for 4 weeks, and 150mg ivacaftor every 12 ...

... failed an active treatment and withdrew during the placebo washout phase, the com- bined response rate was 76. ...

... 17.8) followed by 4 (combined w/ prior placebo disorder/mood disorder, n (%) weeks washout group) 2) 61 (64.9)/33 (35.1) ... 7 (9.6) 2) 2.4 VE and Washout periods 2) 47.2 (11.2) 3) 2.2 2) VBZ 40 mg/day, n=97 3) 47.6 (13.6) (combined w/ prior placebo group) Male, n (%) 1) 34 (68.0) 3) ...

... doses of brodalumab URIs (≥5% in any or placebo DLQI: HADS-A (treatment group): Exclusion: A washout difference, after 1) 8.2, 2) 8.1, 3) 6.4 period was required NR imputation): for patients receiving PsA (%): 1) -1.3, 2) -1.5 ... supplementary p<0.001 appendix) Previous biologics (%): HADS- ...

... 2 week baseline–4 weeks of drug or placebo–1 week washout–4 weeks of Limitations to generalizability: This sample ...

... but partially recovered to LVEF 50% during the washout period. Three patients on mavacamten and three patients on placebo temporarily discontinued due to changes in QT interval. ...

... oxycodone 4) 73.7 (14.9) 20mg or placebo in a double- 5) 75.4 (16.8) blind, crossover with 24-hr 6) 52.7 (13.4) washout between. *p<0.0001 vs. IR oxycodone Intact ...

... determined during the prerandomization period. Following a drug washout period of 4 weeks, if patients were on prior therapy they were given a bottle containing placebo, identical in appearance to the drugs used in ...